Navigation Links
Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Date:7/18/2008

ANN ARBOR, Mich., July 18 /PRNewswire/ -- Velcura Therapeutics, Inc. CEO Michael Long, Ph.D., announced that William F. Brinkerhoff has joined the Board of Directors of the biotechnology company, which completed a first-in-man clinical trial for VEL-0230, a powerful anti-inflammatory agent stimulating bone formation and inhibiting bone loss. Velcura is investigating its lead compound as a treatment for rheumatoid arthritis and other bone diseases.

Bill Brinkerhoff is the chief operating officer of Cerenis Therapeutics, which is focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases.

"In joining Velcura's Board, I look forward to assisting them in their mission of developing therapies that restore bone health," said Bill Brinkerhoff.

Before founding Cerenis in 2005, Brinkerhoff was vice president of business development for Esperion Therapeutics in Ann Arbor, where he successfully negotiated multiple large potential partnering agreements prior to Esperion's acquisition by Pfizer. Before joining Esperion in 2002, he was the director of business development and director of market planning and sales operations, for Sankyo Parke Davis in Parsippany, New Jersey.

A graduate of the University of Michigan, Brinkerhoff earned his Master of Business Administration with Distinction in 1989. He also has bachelor's and master's degrees in Industrial Engineering and Operations Research from U-M's College of Engineering.

Velcura's other directors are Michael W. Long and Bill Orobone, CEO of Syneptics, an alternative energy financing entity.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building and bone loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize these compounds. More information is at http://www.velcura.com .
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
6. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... ... , ... Coast Dental Fort Stewart is celebrating its grand opening with an ... Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, ... have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group ... of their physicians has been invited to be a featured speaker at the Texas ... conference on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine ...
Breaking Medicine News(10 mins):